{
    "ticker": "BBIO",
    "name": "BridgeBio Pharma, Inc.",
    "description": "BridgeBio Pharma, Inc. is a biotechnology company dedicated to developing breakthrough medicines for genetic diseases and cancers. Founded in 2015 by a team of experienced scientists, entrepreneurs, and industry leaders, BridgeBio focuses on utilizing its proprietary platform to identify and advance innovative therapies based on genetic insights. The company's mission is to bring life-changing treatments to patients with high unmet medical needs by leveraging cutting-edge science and research. BridgeBio's portfolio includes several product candidates in various stages of clinical development, with a focus on rare genetic disorders and oncology. The company collaborates with leading academic institutions and research organizations to enhance its scientific capabilities and accelerate the drug development process. BridgeBio is committed to transparency and patient-centricity, ensuring that its therapies are not only effective but also accessible to those who need them most. The company aims to redefine the way genetic diseases are treated, establishing itself as a leader in the biotechnology space.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Palo Alto, California, USA",
    "founded": "2015",
    "website": "https://www.bridgebio.com",
    "ceo": "Andrew B. Hirsch",
    "social_media": {
        "twitter": "https://twitter.com/BridgeBio",
        "linkedin": "https://www.linkedin.com/company/bridgebio-pharma"
    },
    "investor_relations": "https://investors.bridgebio.com",
    "key_executives": [
        {
            "name": "Andrew B. Hirsch",
            "position": "CEO"
        },
        {
            "name": "William A. Hearl",
            "position": "Co-Founder & Executive Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "BBP-398",
                "BBP-812"
            ]
        },
        {
            "category": "Genetic Disorders",
            "products": [
                "BBP-831",
                "BBP-265"
            ]
        }
    ],
    "seo": {
        "meta_title": "BridgeBio Pharma, Inc. | Innovative Medicines for Genetic Diseases and Cancers",
        "meta_description": "Explore BridgeBio Pharma, Inc., a biotechnology company focused on developing transformative therapies for genetic diseases and cancers through innovative research.",
        "keywords": [
            "BridgeBio",
            "Biotechnology",
            "Genetic Diseases",
            "Oncology",
            "Pharmaceuticals",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does BridgeBio Pharma focus on?",
            "answer": "BridgeBio Pharma focuses on developing innovative therapies for genetic diseases and cancers."
        },
        {
            "question": "Who is the CEO of BridgeBio Pharma?",
            "answer": "Andrew B. Hirsch is the CEO of BridgeBio Pharma, Inc."
        },
        {
            "question": "Where is BridgeBio Pharma headquartered?",
            "answer": "BridgeBio Pharma is headquartered in Palo Alto, California, USA."
        },
        {
            "question": "What are some of BridgeBio's key product candidates?",
            "answer": "Some key product candidates include BBP-398, BBP-812, BBP-831, and BBP-265."
        },
        {
            "question": "When was BridgeBio Pharma founded?",
            "answer": "BridgeBio Pharma was founded in 2015."
        }
    ],
    "competitors": [
        "VRTX",
        "REGN",
        "BMRN",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "CELG"
    ]
}